LENSAR logo
LENSAR LNSR
$ 7.08 0.28%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

LENSAR Balance Sheet 2025-2011 | LNSR

Brief overview of LENSAR's assets and capital

Balance sheet changes are traced across five available annual reports between 2021 and 2025.

Across five periods, assets reached $71.4 million versus $66.5 million initially. Growth of +7.5% reflects gradual development.

Funding shifted toward liabilities: they gained +622.1%, compared with +7.5% for assets.

Negative shareholders' equity signals an accumulated net asset deficit and calls for particular caution.

Net debt moved below zero to -$10.2 million, reflecting surplus cash over debt.

The cash share moved from 47.6% to 18.2%. A higher figure generally provides more room in an adverse scenario.

The balance sheet includes a negative accumulated result of -$177.6 million. It should be assessed alongside historical profits and capital distributions.

Overall assessment

LENSAR's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.

Annual Balance Sheet LENSAR

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-10.2 M -13.6 M -18.3 M -11.9 M -28.3 M -37.3 M 15.9 M - - - - - - - -

Long Term Debt

1.99 M 2.09 M 1.75 M 2.27 M 2.8 M - 20.2 M - - - - - - - -

Long Term Debt Current

747 K 524 K 559 K 531 K 512 K 493 K - - - - - - - - -

Total Non Current Liabilities

- - - - - 3.44 M 57.3 M - - - - - - - -

Total Current Liabilities

40.6 M 15 M 11.6 M 11.4 M 8.71 M 8.47 M - - - - - - - - -

Total Liabilities

83.7 M 47.7 M 22.4 M 13.9 M 11.6 M 11.9 M 65.1 M - - - - - - - -

Deferred Revenue

2.6 M 1.68 M 1.35 M 768 K 904 K 923 K 777 K - - - - - - - -

Retained Earnings

-178 M -143 M -112 M -97.5 M -77.6 M -58 M -38.2 M - - - - - - - -

Total Assets

71.4 M 66.3 M 69.6 M 55.8 M 66.5 M 79.1 M 34.5 M - - - - - - - -

Cash and Cash Equivalents

13 M 16.3 M 20.6 M 14.7 M 31.6 M 40.6 M - - - - - - - - -

Book Value

-12.2 M 18.6 M 47.2 M 42 M 54.9 M 67.2 M -30.6 M - - - - - - - -

Total Shareholders Equity

-26 M 4.86 M 33.4 M 42 M 54.9 M 67.2 M -30.6 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet LENSAR

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

1.99 M 1.79 M 2.09 M 2.19 M 1.81 M 1.96 M 2.09 M 1.32 M 1.46 M - 1.75 M 1.89 M 2.03 M 2.17 M 2.27 M 2.41 M 2.54 M 2.67 M 2.8 M 2.93 M 3.06 M 3.19 M 3.31 M 3.31 M 3.31 M 3.31 M 333 K 333 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

83.7 M 41.6 M 47.7 M 82.3 M 79.7 M 81.3 M 47.7 M 25.5 M 24 M - 22.4 M 20.7 M 24.8 M 12.5 M 13.9 M 12.2 M 13.8 M 10.5 M 11.6 M 11.1 M 10.9 M 9.21 M 11.9 M 11.9 M 11.9 M 11.9 M 65.1 M 65.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

3.07 M 2.5 M 1.68 M 2.21 M 2.53 M 1.99 M 1.68 M 1.44 M 1.41 M - 1.35 M 1.06 M 1.07 M 1.03 M 768 K 789 K 937 K 989 K 904 K 922 K 1.07 M 967 K 923 K 923 K 923 K 923 K 777 K 777 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-178 M -141 M -143 M -176 M -172 M -171 M -143 M -125 M -123 M - -112 M -108 M -111 M -102 M -97.5 M -95 M -91 M -84.3 M -77.6 M -73.7 M -67.5 M -63.2 M -58 M -58 M -58 M -58 M -38.2 M -38.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

71.4 M 66.2 M 66.3 M 70.2 M 70.4 M 73 M 66.3 M 62 M 61.4 M - 69.6 M 70.9 M 71.2 M 52 M 55.8 M 54.8 M 58.7 M 60.3 M 66.5 M 68.1 M 72.5 M 73.5 M 79.1 M 79.1 M 79.1 M 79.1 M 34.5 M 34.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

13 M 12.5 M 16.3 M 7.64 M 7.15 M 19.5 M 16.3 M 10.4 M 8.29 M - 20.6 M 24.9 M 25.5 M 7.97 M 14.7 M 19.3 M 25.2 M 29 M 31.6 M 32.3 M 34.6 M 35.9 M 40.6 M 40.6 M 40.6 M 40.6 M 4.62 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

-12.2 M 24.6 M 18.6 M -12.1 M -9.27 M -8.36 M 18.6 M 36.5 M 37.4 M - 47.2 M 50.1 M 46.4 M 39.4 M 42 M 42.6 M 44.9 M 49.8 M 54.9 M 57 M 61.6 M 64.3 M 67.2 M 67.2 M 67.2 M 67.2 M -30.6 M -30.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

4.86 M 10.8 M 33.4 M -25.9 M -23.1 M -22.1 M 4.86 M 22.7 M 23.6 M 31.8 M 33.4 M 36.4 M 32.7 M 39.4 M 42 M 42.6 M 44.9 M 49.8 M 54.9 M 57 M 61.6 M 64.3 M 67.2 M 67.2 M 67.2 M 67.2 M -30.6 M -30.6 M -24.4 M -21.7 M -20.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of LENSAR, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 64.0 7.26 % $ 9.72 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 44.68 0.06 % $ 66.1 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.7 0.06 % $ 634 M israelIsrael
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.61 13.03 % $ 414 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 45.18 3.31 % $ 1.4 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 4.3 1.63 % $ 268 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 16.08 0.75 % $ 576 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Electromed Electromed
ELMD
$ 27.86 1.05 % $ 230 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 65.58 3.69 % $ 1.94 B costa-ricaCosta-rica
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 85.73 0.32 % $ 50.1 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 5.57 0.43 % $ 753 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.9 0.69 % $ 63.9 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 15.88 2.25 % $ 1.22 B usaUSA
Inogen Inogen
INGN
$ 5.23 2.75 % $ 139 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.19 0.21 % $ 917 M israelIsrael
Inspire Medical Systems Inspire Medical Systems
INSP
$ 68.81 0.59 % $ 2.02 B usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.63 2.51 % $ 10.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.2 0.08 % $ 1.08 B usaUSA
AxoGen AxoGen
AXGN
$ 43.32 0.48 % $ 1.99 B usaUSA
Align Technology Align Technology
ALGN
$ 145.63 4.36 % $ 10.6 B usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 88.51 0.32 % $ 113 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.71 0.1 % $ 696 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Myomo Myomo
MYO
$ 1.67 1.83 % $ 69.9 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.66 0.45 % $ 42.8 M israelIsrael
InspireMD InspireMD
NSPR
$ 0.7 0.37 % $ 45 M israelIsrael
Orthofix Medical Orthofix Medical
OFIX
$ 9.16 0.11 % $ 363 M curacaoCuracao
Outset Medical Outset Medical
OM
$ 3.13 1.29 % $ 47.6 K usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 135.78 0.01 % $ 9.55 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.6 1.66 % $ 169 M canadaCanada
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.18 0.63 % $ 136 M usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
AVITA Medical AVITA Medical
RCEL
$ 11.58 5.75 % $ 323 M australiaAustralia
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.83 1.37 % $ 116 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.87 5.06 % $ 5.19 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.22 0.4 % $ 27 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 26.68 0.02 % $ 23.1 B britainBritain
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA